FDA is enhancing one of the agency’s most viewed databases for industry, the Paragraph IV Patent Certifications List, which provides information about exclusivity related to generic challenges of patents on “brand” drug products (180-day exclusivity).
from FDA Press Releases RSS Feed http://bit.ly/31Fdeam
via IFTTT
No comments:
Post a Comment